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Summary Objective: Human aminopeptidase N (APN/CD13/ANPEP) has been iden-
tiﬁed as the receptor for human coronavirus (HCoV) 229E. In this study, we analyzed
the region of the APN gene that encodes a stretch of amino acid residues, essential
for its HCoV-229E receptor function (amino acids 260—353).
Methods: Full-length APN exon 3, intron 3 and exon 4, was PCR-ampliﬁed and se-
quenced in DNA samples from 100 unrelated Caucasian Belgian healthy volunteers.
Results: We identiﬁed seven polymorphisms, including four intron 3 and three exon
4 variations. Apart from the already known C956T exon 4 mutation, the six other
polymorphisms have not yet been described. The most prevalent APN variations in
this population (C956T leading to an alanine to valine substitution, G978T, G987A and
intron3-C389T) always occurred together at an allele frequency of 8.5%. Haploid DNA
sequencing demonstrated the presence of these four variations on the same allele.
Three polymorphisms in intron 3, intron3-G395C, intron3-C86T, and intron3-C429T,
were identiﬁed with an allele frequency of 3.5%, 1% and 0.5% respectively. Five hap-
lotypes were identiﬁed in the population of 100 individuals.
Conclusion: These results demonstrate that there is a relatively broad spectrum of
variations in the APN domain critical for coronavirus binding.
The nucleotide sequence reported here has been submitted to the GenBank database
with the following accession number: AF527789.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
Coronaviruses are large, enveloped, single-stranded,
positive-sense RNA viruses, with a genome size of
approximately 30 kb. Human coronaviruses (HCoV),
with two known serogroups designated OC43 and
229E, are an important cause of upper respiratory
tract illnesses, and are also implicated in diseases
involving the digestive and the central nervous
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system.1 After the recent SARS outbreak and the
discovery of a new coronavirus (SARS-CoV) as the
causative agent, the importance of coronaviruses
in human medicine can no longer be neglected.2
As a ﬁrst step in viral entry into the cell, hu-
man coronavirus 229E (HCoV-229E) attaches, in
a species-speciﬁc manner, to aminopeptidase
N (APN/CD13/ANPEP).3 In other species APN is
also used as a receptor by the HCoV-229E re-
lated group I coronaviruses (porcine transmissible
gastroenteritis virus, porcine epidemic diarrhea
virus, feline infectious peritonitis virus and ca-
nine coronavirus).4,5 Although human APN had also
been suggested as a putative receptor for the spike
glycoprotein of the SARS-associated coronavirus
(SARS-CoV), it has now been proven that not APN
but angiotensin-converting enzyme 2 is a functional
receptor for SARS-CoV.6,7 The receptor for human
coronavirus serotype OC43 (HCoV-OC43) is still un-
known, although evidence has been presented that
9-O-acetylated sialic acid is used as a receptor
determinant for infection of human cells.8
APN is a type II glycoprotein that belongs to the
family of membrane-bound metalloproteases. The
150 kDa APN glycoprotein (EC 3.4.11.2) is com-
posed of 967 amino acids and is expressed in a
variety of tissues including cells of the monocytic
and granulocytic lineage, synaptic membranes of
the central nervous system, and intestinal, lung
and kidney epithelial cells.9 A soluble form of APN
is reported to be present in human plasma.10 The
physiological role of APN includes the conversion
of oligopeptides in the small intestinal lumen into
amino acids, and an involvement in the degrada-
tion of regulatory peptides in other tissues such as
the kidney and the brain.9 The human APN gene has
been mapped to chromosome 15q25-26, and the
coding part of the gene is divided in 20 exons.11,12
Expression of APN is regulated by two different
promoters, separated by an 8 kb intron, leading to
the formation of two transcripts that only differ in
their 5′ non-coding region. The epithelial promoter
is located close to the coding part of the gene
and is active in enterocytes and other epithelial
cells, while the more upstream myeloid promoter
is mainly active in myeloid cells.13 Two splice vari-
ants in which exon 3 and exon 14 were lost, have
recently been identiﬁed, resulting in both cases in
a carboxy-terminal truncated protein.14
Several applications of APN in therapy and diag-
nosis have been described. APN/CD13 is frequently
used in the characterization and typing of leukemia
or lymphoma cells, as APN/CD13 is expressed on
stem cells and during most developmental stages of
myeloid cells.15 It has recently been demonstrated
that APN/CD13 is both a receptor for tumor homing
peptides and a functional regulator of angiogene-
sis, implicating a role for APN/CD13 as a target for
anti-angiogenic therapy and tumor targeted drug
delivery.16,17 APN has also been shown to mediate
human cytomegalovirus (HCMV) infection.18 The in-
hibition or neutralization of HCMV infection by sol-
uble APN implicates the possibility of using soluble
APN as an antiviral agent.
The domain of human aminopeptidase N that is
essential for its HCoV-229E receptor activity has
been assigned to APN amino acids 260—353, with
a critical stretch of eight residues (amino acids
288—295).19,20 This region is encoded by the ma-
jor part of APN exon 3, whole exon 4 and a small
part of APN exon 5 (nt 802—1083, hAPN mRNA,
GenBank accession number X13276). In this study
we examined whether polymorphisms could be de-
tected in the HCoV-229E binding domain of APN in a
Caucasian population of 100 unrelated, healthy in-
dividuals, assuming that these mutations could be
of importance in HCoV-229E attachment to human
cells.
Materials and methods
Subjects
The study involved a Caucasian population of 100
healthy, unrelated individuals from the region of
Flanders, the northern part of Belgium. Informed
consent was obtained from all participants and the
study had the approval, based upon the guidelines
from the World Medical Association’s Declaration of
Helsinki, of the Ethics Board of the University of
Leuven.21
DNA extraction
DNA samples were collected through a non-invasive
‘swish-and-spit’ technique. Genomic DNA was ac-
quired from oral epithelial cells, by rinsing the oral
cavity with a 0.9% saline solution, after which DNA
was extracted using an alkaline lysis procedure.22
PCR ampliﬁcation
An 871 bp fragment, encompassing exon 3, intron
3 and exon 4 of the aminopeptidase N gene, was
ampliﬁed by polymerase chain reaction (PCR),
using 5′-TGCTTCCCAAAGGTGAGTGG-3′ as the for-
ward primer and 5′-CCATTGGCAGGATGAACTCC-3′
as the reverse primer (GenBank accession number
AC018988). PCR ampliﬁcation was performed in a
volume of 50L reaction mix, with a concentration
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of 0.2M of forward and reverse primer, 0.2mM of
nucleotides, 1.5mM of MgCl2 and 1 unit of Taq poly-
merase (Applied Biosystems/Roche Molecular Sys-
tems, Belgium) at pH 9. PCR conditions were com-
posed as follows: an initial denaturation at 95 ◦C for
ﬁve minutes, then 40 cycles of 30 seconds at 95 ◦C,
30 seconds at 57 ◦C and 35 seconds at 72 ◦C, and a
ﬁnal elongation at 72 ◦C for seven minutes. The am-
pliﬁcation reaction was performed in a Geneamp®
PCR System 9700 thermal cycler (Applied Biosys-
tems, Foster City, CA, USA). The resulting PCR
products were visualized after electrophoresis, on
an ethidium bromide-stained polyacrylamide gel.
Sequence analysis
After puriﬁcation of the PCR products with the
QIAquick PCR puriﬁcation kit (Qiagen, Westburg,
The Netherlands), the puriﬁed products were
cycle sequenced in forward and reverse direc-
tion using the ABI PRISM BigDye Terminator Cycle
Sequencing Ready Reaction kit (Applied Biosys-
tems, Foster City, CA, USA). Besides the PCR
primer set, two additional primers, a forward:
5′-CTGCCCCAGGATCAAACAGG-3′ and a reverse:
5′-GCACAGGGATGAAGAGAACG-3′, both located in
APN intron 3, were used to obtain the full-length
sequence of the 871 bp fragment (GenBank ac-
cession number AJ421875). Electrophoretic sep-
aration and detection were performed on an ABI
PRISM 3100 Genetic Analyzer (Perkin Elmer, Applied
Biosystems, Foster City, CA, USA).
Haplotype analysis
PCR products from individuals heterozygous for
more than one variation were cloned into the
pDrive cloning vector (Qiagen PCR Cloning kit) using
One Shot Max efﬁciency DH5-T1 competent cells
(Invitrogen, Merelbeke, Belgium). Plasmids were
puriﬁed with the Qiaprep miniprep spin kit (Qia-
gen, Westburg, The Netherlands) and checked for
inserts by EcoRI restriction analysis. Bidirectional
cycle sequencing of plasmids with inserts was per-
formed with the PCR primer set using the ABI PRISM
BigDye Terminator Cycle Sequencing Ready Reac-
tion kit (Applied Biosystems, Foster City, CA, USA).
Electrophoretic separation and detection were
performed on an ABI PRISM 3100 Genetic Analyzer
(Perkin Elmer, Applied Biosystems, Foster City, CA,
USA).
Results
A total of 100 healthy unrelated Belgian individu-
als were screened for polymorphisms in the human
aminopeptidase N domain that is essential for its
HCoV-229E receptor activity. An 871 bp fragment,
encompassing APN exon 3, intron 3 and exon 4 was
PCR-ampliﬁed and sequenced, and was submitted
to GenBank under accession number AF527789. The
resulting chromatograms were analyzed using the
SeqMan multiple sequence alignment tool (Laser-
Gene, DNAStar, Madison, WI). Consensus sequences
were compared with a reference APN sequence in
GenBank (accession number AJ421875) using BLAST
(Basic Local Alignment Search Tool).23
Seven variations were identiﬁed, of which six
have not yet been described. Table 1 shows the
distribution of the allele frequencies. Intron vari-
ations are described referring to their relative
position in the intron, and exon variation positions
are referred to their mRNA nucleotide position
(GenBank accession number X13276). The location
of the polymorphisms in the APN gene is shown in
Figure 1. While no variations could be found in APN
exon 3, four of the identiﬁed polymorphisms were
located in intron 3 and three in exon 4. In intron 3,
a C to T variation was found at intron 3 position 86
(C86T) (GenBank AJ421875, contig position 327) in
two individuals, as well as a G to C variation at in-
tron position 395 (G395C) in seven individuals, and
a C to T variation at intron position 429 (C429T)
in one sample. All individuals were heterozygous
Table 1 Allele frequencies of the APN gene
mutations.
Position Variation Frequency
n %
Intron 3a
86 C 198 99.0
T 2 1.0
389 C 183 91.5
T 17 8.5
395 G 193 96.5
C 7 3.5
429 C 199 99.5
T 1 0.5
Exon 4b
956 (codon 311) C 183 91.5
T 17 8.5
978 (codon 318) G 183 91.5
T 17 8.5
987 (codon 321) G 183 91.5
A 17 8.5
a Variations in intron 3 are referred to their position
in intron 3.
b Variations in exon 4 are referred to their mRNA po-
sition (GenBank accession number X13276).
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Figure 1 Schematic representation of the human aminopeptidase N (APN) gene. M represents the myeloid promoter,
and E the epithelial promoter. The primers used in the PCR reaction are indicated by F (forward) and R (reverse).
The locations of the identiﬁed variations are indicated (arrows).
for these polymorphisms, which have no appar-
ent functional consequence, as they are located
in a non-coding intron region of the APN gene.
The fourth observed intron polymorphism, a C to T
variation at intron position 389 (C389T) was found
in association with three variations in exon 4: an
already described C to T polymorphism in codon
311 (GenBank X13276, mRNA, nt position 956),24
leading to an alanine to valine substitution, and
two silent mutations, a G to T variation in codon
318 (nt 978), and a G to A variation in codon 321 (nt
987). Fifteen heterozygotes and one homozygote
for these four polymorphisms were found in the
group of 100 Belgian individuals. In one of these
ﬁfteen heterozygous individuals, the intron varia-
tion C429T was found. No deviations from expec-
tations under Hardy-Weinberg assumptions were
observed.
Haplotypes were determined by sequence anal-
ysis of cloned PCR-amplicons in samples of indi-
viduals heterozygous for more than one variation.
Five haplotypes were identiﬁed, and their frequen-
cies are shown in Table 2. The four linked varia-
tions, identiﬁed in samples of 16 individuals, were
demonstrated to be present on the same allele,
and this haplotype was detected with a frequency
of 8.5%.
Table 2 Distribution of the APN haplotypes.
Intron 3a Exon 4b Frequency
86 389 395 429 956 978 987 n %
C C G C C G G 173 86.5
C T G C T T A 17 8.5
C C C C C G G 7 3.5
T C G C C G G 2 1.0
C C G T C G G 1 0.5
a Variations in intron 3 are referred to their position in intron 3.
b Variations in exon 4 are referred to their mRNA position (GenBank accession number X13276).
Discussion
In this study we analyzed an 871 bp region of the
APN gene, encompassing the full-length APN exon
3, intron 3 and exon 4. In our search for polymor-
phisms in the APN domain that is essential for its
HCoV-229E receptor function, we identiﬁed seven
polymorphisms, of which four were located in the
non-coding intron 3. In 25% of the Belgian individ-
uals one or more of these seven variations were
found. Haplotype analysis revealed the presence of
ﬁve haplotypes in the population. Three polymor-
phisms in APN exon 4 (C956T, G978T and G987A)
in association with an intron 3 variation (C389T),
were identiﬁed at a relatively high allele frequency
(8.5%) in our Belgian population. Fifteen heterozy-
gotes and one homozygote for these four variations
were observed. One of the exon 4 single nucleotide
polymorphisms is a C to T mutation, C956T, lead-
ing to an amino acid change in codon 311. This ala-
nine to valine substitution, a conservative amino
acid change, has already been described in a pop-
ulation of Italian coeliac disease patients, in which
it was observed with an allele frequency of 7.9%.24
In our population, this polymorphism was approx-
imately equally frequent (8.5%). The C956T poly-
morphismwas always found in combination with the
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two other observed exon 4 variations (G978T and
G987A) and one intron 3 variation (C389T). Hap-
loid DNA sequencing demonstrated the presence of
these four variations on the same allele. Here we
report for the ﬁrst time an association between the
C956T polymorphism and other variations in the APN
gene. Absolute linkage between the SNPs within
this short physical distance is commonly observed.
Apart from the codon 311 variation (C956T), none
of the other associated polymorphisms has an ap-
parent functional effect, as the codon 318 and 321
variations (G978T and G987A) are silent, and C389T
is located in an intron.
Recent studies revealed that the human APN gene
is subject to alternative splicing, and two splice
variants, in which exon 3 and exon 14 were lost,
have been identiﬁed.14 Alternative splicing is a
mechanism that allows different protein isoforms to
be created from a single gene. The splicing process
is regulated by both cis- and trans-acting factors,
which control the choice of 5′ or 3′ splice sites either
positively or negatively. Cis-acting regulatory ele-
ments include exonic or intronic splice enhancers
or silencers, which can be changed by mutations
with a possible effect on mRNA splicing.25,26 In this
perspective, the importance of silent mutations or
intron variations, which seem to have no apparent
functional effect, should be reconsidered. Support-
ing this assumption, a silent mutation (C77G) in
exon 4 of the human protein-tyrosine phosphatase
CD45 gene has been shown to increase the ex-
pression of an aberrant exon 4-included CD45 by
disrupting the activity of an exonic splice silencer.
An association of this silent mutation with multiple
sclerosis has been suggested.27 In this way, it might
be possible that the silent mutations in APN exon 4
and the APN intron 3 variations that we observed in
our population could be of functional importance.
The alanine to valine substitution in codon 311,
caused by the single nucleotide polymorphism
C956T, is an amino acid change occurring in the
APN domain that is essential for its HCoV-229E re-
ceptor function. Although this amino acid variation
is rather conservative, an effect on the HCoV-229E
binding capacity of aminopeptidase N could be
possible. Since the three-dimensional structure of
APN has not yet been described, molecular mod-
eling studies of the whole protein could not be
performed.
Further research is needed to elucidate the bi-
ological relevance of the APN variations described
here. In vitro studies should be carried out includ-
ing in vitro transcription, translation and viral bind-
ing assays of the described APN gene variants to
detect a possible functional effect. Furthermore, a
virus susceptibility test can be performed involving
healthy volunteers homozygous or heterozygous for
these variations. HCoV-229E is a relatively innocu-
ous agent and it would be possible to determine
whether these polymorphisms could affect suscep-
tibility to infection.
Given the substantial role of aminopeptidase N
in several domains, including disease therapy and
diagnosis, studies analyzing the APN gene and the
functional consequences of possible gene variations
will be of importance in these and future applica-
tions.
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